Company intelligence / Profile preview
UTR Therapeutics
New York, New York, USAutrtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
UTR Therapeutics has submitted an IND application to the US FDA for its lead candidate UTRxM1-18 targeting c-MYC-driven cancers using a proprietary RNA-destabilizing approach. Preclinical data show high specificity and safety in targeting tumor cells with minimal effect on healthy cells. The company is advancing additional programs against MYCN, TEAD1/YAP1 for cancer as well as targets in obesity, MASH, and neurodegeneration
- Therapeutic areas
- OncologyEndocrinologyMetabolic DisordersNeurology
- Modalities
- RNA therapymRNA-based drugs
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
No major partnerships publicly disclosed as of June 2025
Beyond the preview
Go deeper on UTR Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UTR Therapeutics.